Webinar Details

As precision medicine in oncology advances, selecting the right genomic analysis method is key to obtaining accurate and actionable insights. Balancing sensitivity, specificity, cost, and data analysis is crucial for optimizing assay performance.

Whether detecting MRD, identifying mutations, or developing liquid biopsy assays, the choice between qPCR, targeted NGS, and whole-genome NGS directly impacts clinical utility. Understanding the strengths and limitations of these technologies is essential for success.

• How qPCR, targeted NGS, and whole-genome NGS compare in precision medicine applications such as liquid biopsy, MRD monitoring, mutation detection, and hereditary disease screening.
• The advantages and limitations of each approach, including key considerations for sensitivity, throughput, cost, and data requirements.
• Real-world assay examples demonstrating how these technologies are applied in clinical oncology settings.

About the Speaker

Dale Clash, Marketing Manager

Dale brings over 25 years of experience in the clinical diagnostics industry and currently serves as Strategic Marketing Manager at Meridian Bioscience’s Life Science division. She leads commercial marketing efforts for molecular diagnostics, with a focus on advanced technologies like PCR, NGS, and liquid biopsy. Originally trained as a Biomedical Scientist in Cape Town, Dale has worked in hospital labs across South Africa and the UK, and has held industry roles at companies including Becton Dickinson, Werfen, and Thermo Fisher Scientific. She’s passionate about making complex science accessible and helping assay developers bring impactful diagnostics to market.